Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15365139 | 0.96 | MAPT (0.45) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15365263 | 0.96 | ALDH1A1 (0.45) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15366047 | 0.96 | ALDH1A1 (0.45) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5651215 | 0.96 | MAPT (0.45) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15365148 | 0.96 | ALDH1A1 (0.45) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL20866201 | 0.90 | LMNA (0.39) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15365609 | 0.90 | ALDH1A1 (0.41) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15365285 | 0.89 | MAPT (0.40) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15365067 | 0.89 | MAPT (0.40) | MAPTGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL15372369 | 0.87 | LMNA (0.40) | MAPTGRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | claimed |
| CN-112300082-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2021-02-02 | — | — | CN | claimed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | claimed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | claimed |
| CN-122059883-A | Production and preparation method of erlotinib intermediate | 安徽尖峰北卡药业有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-114920704-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-08-19 | — | — | CN | disclosed |
| US-20220235014-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | SHIVALIK RASAYAN LIMITED (IN) | 2022-07-28 | — | — | US | disclosed |
| CN-112300082-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-04-26 | — | — | CN | disclosed |
| WO-2010109443-A1 | PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-30 | — | — | WO | disclosed |
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | CIPLA LIMITED (IN) | 2010-04-15 | — | — | US | disclosed |
| EP-2139868-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cipla Limited (IN) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122776-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LIMITED (IN) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138612-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138613-A2 | A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094004-A1 | Process for Preparation of Erlotinib and its Pharmaceutically Acceptable Salts | ABL1, EGFR, KRAS | MAPT 2403/4885GRIA1 2824/4885GRIA2 2299/4885 |
| US-20220235014-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | EGFR, KRAS, ERBB4 | MAPT 4008/4885GRIA1 3809/4885GRIA2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.